Rigel Pharmaceuticals Inc. (New) (RIGL) Stock Price

RIGLStock

$45.97+63.54%52W

Market Cap$850.54M

P/E2.34x

PEG Ratio—

Div yield—

Beta1.27

RIGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)36.54%

Price vs S&P 500 (4W)-1.05%

VGM Score65.73

P/E Ratio (Annual)2.34x

P/CF (Annual)11.35x

Book Value / Share (Quarterly)$22.81

P/TBV (Annual)2.12x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)34.78%

Cash Flow / Share (Quarterly)$0.48

Price vs S&P 500 (YTD)-4.60%

Gross Margin (TTM)91.39%

Net Profit Margin (TTM)116.30%

EPS (TTM)$16.04

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$16.04

Revenue Growth (5Y)22.06%

EPS (Annual)$19.48

ROI (Annual)82.71%

Gross Margin (Annual)93.33%

Net Profit Margin (5Y Avg)10.45%

Cash / Share (Quarterly)$5.11

P/E Basic Excl Extra (TTM)2.67x

Revenue Growth QoQ (YoY)-22.60%

P/E Normalized (Annual)2.34x

ROA (Last FY)71.46%

Revenue Growth TTM (YoY)3.31%

EBITD / Share (TTM)$4.49

ROE (5Y Avg)70.99%

Operating Margin (TTM)31.45%

Cash Flow / Share (Annual)$4.13

P/B Ratio2.02x

P/B Ratio (Quarterly)1.70x

Net Income / Employee (Annual)$2,133,900

EV / Revenue (TTM)3.02x

Net Interest Coverage (TTM)34.48x

ROA (TTM)72.27%

EPS Growth QoQ (YoY)-73.08%

EV / EBITDA (TTM)9.49x

EPS Incl Extra (Annual)$19.48

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume0.31M

52-Week Price Return63.54%

EV / Free Cash Flow (Annual)11.07x

P/E Incl Extra (TTM)2.67x

Revenue / Employee (TTM)$1,609,200

Tangible BV / Share (Quarterly)$17.77

P/S Ratio (Annual)2.92x

Asset Turnover (Annual)0.57x

52-Week High$52.24

Operating Margin (5Y Avg)-3.21%

EPS Excl Extra (Annual)$19.48

CapEx CAGR (5Y)-22.97%

26-Week Price Return46.45%

Quick Ratio (Annual)2.08x

13-Week Price Return13.39%

Total Debt / Equity (Annual)0.13x

Current Ratio (Quarterly)1.94x

Enterprise Value$837.13M

Revenue / Share Growth (5Y)89.25%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)100.65%

Revenue / Employee (Annual)$1,710,900

Inventory Turnover (Annual)2.24x

Pretax Margin (Annual)41.40%

Cash / Share (Annual)$8.46

3-Month Return Std Dev40.20%

Gross Margin (5Y Avg)94.95%

Net Income / Employee (TTM)$1,871,600

EBITDA Interim CAGR (5Y)-22.31%

ROE (Last FY)93.75%

Net Interest Coverage (Annual)47.82x

EPS Basic Excl Extra (Annual)$19.48

P/FCF (TTM)10.83x

Receivables Turnover (TTM)5.77x

EV / Free Cash Flow (TTM)92.58x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$16.04

Receivables Turnover (Annual)6.30x

ROI (TTM)84.13%

P/S Ratio (TTM)3.10x

Pretax Margin (5Y Avg)-6.04%

Revenue / Share (Annual)$15.62

Tangible BV / Share (Annual)$20.03

Forward P/E12.00x

Price vs S&P 500 (52W)48.00%

P/E Ratio (TTM)2.67x

EPS Growth TTM (YoY)196.12%

Year-to-Date Return7.33%

5-Day Price Return-5.82%

EPS Normalized (Annual)$19.48

ROA (5Y Avg)1.28%

Net Profit Margin (Annual)124.72%

Month-to-Date Return-4.53%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$6.79

Operating Margin (Annual)42.63%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)10.82x

ROI (5Y Avg)-17.10%

P/E Excl Extra (TTM)2.67x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$16.04

P/TBV (Quarterly)2.18x

P/B Ratio (Annual)1.99x

Inventory Turnover (TTM)1.92x

Pretax Margin (TTM)30.92%

Book Value / Share (Annual)$21.38

Price vs S&P 500 (13W)10.71%

Beta1.27x

P/FCF (Annual)11.35x

Revenue / Share (TTM)$14.14

ROE (TTM)96.49%

52-Week Low$24.95

vGradeB

gGradeC

mGradeA

vgmGradeB

RIGL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.08	$0.88	+1266.80%(+$0.96)
Q1 2026	May 5, 2026	$0.87	$0.44	-49.54%(-$0.43)
Q4 2025	Mar 3, 2026	$1.20	$1.12	-6.80%(-$0.08)
Q3 2025	Nov 4, 2025	$0.94	$1.46	+56.03%(+$0.52)
Q2 2025	Aug 5, 2025	$1.41	$3.28	+133.45%(+$1.87)

RIGL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.09

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RIGLRigel Pharmaceuticals Inc. (New)	B	C	A	3.1x	3.3%	91.4%	—	$45.97
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals develops small-molecule therapeutics for autoimmune, cancer, and viral diseases. The company markets TAVALISSE, an oral SYK inhibitor, and generates revenue through a partnership with AstraZeneca for an oral rheumatoid arthritis candidate, earning royalties and milestone payments. Its pipeline includes additional candidates targeting SYK and JAK pathways.

RIGL Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.96

Revenue estimate$80.10M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

FMCFMC CorporationChemicals
FTKFlotek Industries, Inc.Industrial Chemicals
SLBTSL Science Holding Limited Ordinary SharesBiological Products
KROKronos Worldwide, Inc.Industrial Chemicals
CGEMCullinan Therapeutics, Inc. Common StockBiological Products
GLUEMonte Rosa Therapeutics, Inc. Common StockBiological Products
ODTXOdyssey Therapeutics, Inc. Common StockBiological Products
LXULSB INDUSTRIES INCIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$24.95

High$52.24